Drug price listing and insurance coverage approved. Telomerase injection will be marketed through FujiFilm Toyama Chemical starting August 21, 2026. Revenue recognition is expected from the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"OncoTherapies BioPharma Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-08-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4588-20260812-01.pdf","jir_short_summary":"Drug price listing and insurance coverage approved. Telomerase injection will be marketed through FujiFilm Toyama Chemical starting August 21, 2026. Revenue recognition is expected from the fiscal year ending December 2026.","jir_summary":"### Key points of the news\nFormal decision on drug price listing and insurance coverage for Telomerase injection. Sales to commence through the marketing partner, with revenue recognition scheduled from the fiscal year ending December 2026.\n\n### Outlook and impact\nAnticipated market introduction as coverage begins. However, concrete impact on earnings is under review, and the timing and magnitude of revenue contribution are unknown. Launch date is August 21, 2026, and the price listing indicates the benchmark amount borne by patients.","jir_financial_highlights":"Calculated price: 3,102,489 yen (per patient 9,307,467 yen) (Unknown)\nLaunch date: August 21, 2026 (Unknown)\nImpact on financial period: Undetermined (under review) (Unknown)\nRevenue recognition start: Expected from the fiscal year ending December 2026 (Unknown)","jir_category":"","jir_hashtags":"#OncoBioPharma, Unrelated to share buybacks; excluded","jir_key_figures":"Calculated price: 3,102,489 yen (per patient 9,307,467 yen)\nLaunch date: August 21, 2026\nRevenue recognition start: Expected from the fiscal year ending December 2026","jir_meta_title":"\u3010OncoBioPharma\u3011Tumor Lysis Virus Price Listing and Insurance Coverage Announcement\uff5cAugust 2026","jir_meta_description":"OncoBioPharma announces price listing and insurance coverage for Telomerase injection. Sales start on August 21, 2026, with revenue recognition expected from the December 2026 quarter. Impact on earnings is under review.","jir_og_title":"\u3010OncoBioPharma\u3011Price Listing and Insurance Coverage Notice","jir_og_description":"Price listing and insurance coverage for Telomerase injection have been decided. Sales start on August 21, and revenue recognition begins in the December quarter. Impact on earnings is under review.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-101726","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n